Citations

Clear

2303 citation(s) found for "Yu, Edward".

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma
Usmani, Saad, Bories, Pierre, Gasparetto, Cristina, Dingli, David, Lonial, Sagar, Siegel, David, Yee, Andrew, Varga, Cindy, Trudel, Suzanne, Dachs, Laura Rosiñol, Rodriguez-Otero, Paula, Manier, Salomon, Berdeja, Jesús, Afrough, Aimaz, Baker, Warren, Hasheminasab, Seyed Alireza, Thakurta, Anjan, Sridharan, Vinidhra, Flynt, Erin, Barnett, Miriam, Versmee, Laura, Mateos, María-Victoria, Touzeau, Cyrille, Chung, Alfred, Roy, Vivek, Stadtmauer, Edward, Usmani, Saad, Bories, Pierre, Gasparetto, Cristina, Dingli, David, Lonial, Sagar, Siegel, David, Yee, Andrew, Varga, Cindy, Trudel, Suzanne, Dachs, Laura Rosiñol, Rodríguez‐Otero, Paula , Manier, Salomon, Berdeja, Jesús, Afrough, Aimaz, Baker, Warren, Hasheminasab, Seyed Alireza, Thakurta, Anjan, Sridharan, Vinidhra, Flynt, Erin, Barnett, Miriam, Versmee, Laura, Mateos, María-Victoria, Touzeau, Cyrille, Chung, Alfred, Roy, Vivek, Stadtmauer, Edward

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 250-250

10.1182/blood-2025-250 Get It

Abstract Background Translocation of chromosomes 4 and 14 (t(4;14)) results in overexpression of MMSET and has been associated with poor clinical outcomes in patients (pts) with multiple myeloma (MM). KTX-1001 is a first-in-class, potent, and selective oral inhibitor of MMSET (also known as NSD2) developed as the first investigational therapy to directly target the high-risk t(4;14) translocation, a key molecular driver in MM. KTX-1001 binds to and inhibits the catalytic SET domain of MMSET, thereby suppressing the deposition of dimethylated histone H3 lysine 36 (H3K36me2), leading to downregulation of oncogenic histone modifications and epigenetic reprogramming of malignant plasma cells. Preclinically, KTX-1001 synergistically inhibited cell viability in MM cell lines when combined with a proteasome inhibitor (PI), immunomodulatory drug (IMiD), or cereblon E3 ligase modulator (CELMoD™). Preliminary findings were previously reported from the initial cohort of 18 pts enrolled in a first-in-human phase 1 trial evaluating KTX-1001 in relapsed/refractory multiple myeloma (RRMM; NCT05651932; Bories et al. Blood. 2024;144[Suppl 1]:3370). Here, we present updated results from this study. Methods RRMM pts who received ≥3 prior therapies, including PI, IMiD and anti-CD38 monoclonal antibody (anti-CD38 mAb), received oral KTX-1001 across 9 dose levels using a 3+3 dose-escalation design. Primary objective was to determine the recommended Phase 2 dose (RP2D) and the maximum tolerated dose (MTD). Secondary objectives included pharmacokinetics, pharmacodynamics (PD), and primary efficacy. The dose expansion phase has been initiated to evaluate KTX-1001 in combination with either carfilzomib or the investigational CELMoD™ mezigdomide in t(4;14) RRMM pts. Results As of 13 June 2025, 40 pts have been treated in the monotherapy dose-escalation phase. The maximum tolerated dose (MTD) was exceeded due to dose-limiting toxicities (DLTs) in 2 pts: two Grade (Gr) 4 thrombocytopenia and one Gr 3 epistaxis. Backfill at selected dose levels is ongoing to further characterize safety profile and refine dose optimization. The median time from initial MM diagnosis was 8 years (range:2-20) with a median of 6.5 prior lines of therapy (range: 3-25). This included stem cell transplant (70%), BCMA CAR-T (42.5%), and non-CAR-T BCMA targeted drugs such as antibody-drug conjugates and bispecific antibodies (57.5%). The median age was69 years (range:50-83); 21 were female and 19 were male. Extra-medullary disease was present in 13 (32.5%) pts. Nineteen (47.5%) pts had t(4;14) translocation, 5 (12.5%) had 1q21 gain and 4 (10%) had deletion 17p. A total of 16 (40%) pts have shown a treatment response according to IMWG criteria or have achieved stable disease: 1 VGPR (10+ months), 1 PR (4+ months), 2 MR (3+ and 12 months), 12 SD (2-20+ months). KTX-1001 has demonstrated a favorable tolerability profile. Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 31 (77.5%) pts. The most frequent (≥20% pts) Gr 3/4 TEAEs were thrombocytopenia in 12 pts (30%; grade 4 in 8 [20%]), neutropenia in 12 pts (30%; febrile neutropenia in 2 [5%]), anemia in 10 (25%) pts. Gr 3 infections were observed in 5 (12.5%) pts and fatigue in 5 (10%) pts. The main reason for treatment discontinuation was progressive disease (57.5%), other pts discontinued due to physician decision (5%), consent withdrawal (5%), and one pt due to adverse event. Twelve (30%) pts remain on treatment. At Cycle 1 Day 15, drug exposure and steady-state concentrations of KTX-1001 increased with dose. A dose-dependent reduction in H3K36me2, the primary PD marker of KTX-1001 activity, was observed in peripheral blood at Cycle 2 Day 1 and beyond, which plateaued above dose-level 4. Paired bone marrow samples further confirmed on-target PD effects, with a marked reduction in H3K36me2 levels in MM cells at Cycle 2 Day 1 with observed anti-MM effect of reduced proliferation of MM cells with concomitant increased proliferation in immune cells in pts achieving clinical benefit. ConclusionsKTX-1001 is a novel agent showing tolerable safety profile in RRMM and demonstrating promising single agent activity in heavily pretreated, triple class refractory RRMM including those with high-risk features. KTX is currently evaluated in ongoing study in combination with carfilzomib and the investigational CELMoD™ mezigdomide in t(4;14) RRMM pts.
Evaluation of Emergency Medicine Pharmacist Participation in Time to Oral Anticoagulation Reversal: A Systematic Review and Meta‐Analysis
Brown, Caitlin S. , Engstrom, Kellyn , Faine, Brett , Mattson, Alicia E , Cole, Kristin, Acquisto, Nicole M. , Wieruszewski, Erin D. , Mercer, Kevin , Gerberi, Dana , Brown, Caitlin S , Faine, Brett A , Mattson, Alicia, Acquisto, Nicole M , Wieruszewski, Erin , Mercer, Kevin , Rech, Megan A , Gilbert, Brian W. , Cole, Kristin, Bellolio, Fernanda , Rabinstein, Alejandro A. , Rech, Megan A.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | November 28, 2025 | Volume: 9 | Issue: 2 | Pages: No page available

10.1002/jac5.70156 | PMID 42009489 Get It

ABSTRACT Background Intracranial and extracranial hemorrhages are significant causes of morbidity and mortality. Emergency medicine pharmacists (EMPs) can play a crucial role in anticoagulation reversal by identifying patients on anticoagulation, selecting the optimal anticoagulation reversal agent, and ensuring adequate dosing and prompt administration. The goal of this systematic review and meta‐analysis was to determine the impact EMPs have on time to anticoagulation reversal and patient outcomes in anticoagulation‐associated hemorrhages. Methods A medical librarian performed a literature search in EBSCO CINAHL, Ovid Cochrane Central Register of Controlled Trials, Ovid Embase, Ovid Medline, Scopus, and Web of Science Core Collection from inception to January 2025 for all types of oral anticoagulants and for life‐threatening bleeding that required emergent reversal. Newcastle‐Ottawa was used to assess the risk of bias, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the level of certainty of the evidence. Random effects models estimating mean differences and 95% confidence intervals are reported. Results There were 2445 titles and abstracts screened, with 44 undergoing full‐text evaluation. Six observational studies including 219 patients who received an anticoagulation reversal agent with the presence of an EMP and 198 patients who received a reversal agent without an EMP were included. Time from emergency department (ED) presentation to anticoagulation reversal agent administration (75.60 min, 95% confidence interval [CI]: −101.7 to −49.5) and time from medication order to administration were faster with an EMP (−18.7 min, 95% CI: −23.5 to −14.0). There was no difference in short‐term mortality. The included studies had a high risk of bias and were deemed very low quality of evidence. Conclusion EMP involvement in patient care during anticoagulation reversal of acute hemorrhages improved time to anticoagulation reversal agent administration. Larger scale, higher‐quality studies are necessary to assess the value of EMPs in improving patient‐centered outcomes.
Socioeconomic position and its effect on cardiovascular outcomes and mortality in patients with prostate cancer
Nahle, Tarek , Shah, Viraj , Kunhiraman, Harikrishnan Hyma , Afzal, Muhammad Umar , Riaz, Irbaz Bin , Agarwal, Neeraj , Swami, Umang , Rachoin, Jean-Sébastien , Weintraub, Neal L, Guha, Avirup , Makram, Omar M , Shah, Viraj R , Hyma Kunhiraman, Harikrishnan , Afzal, Muhammad Umar , Riaz, Irbaz B , Agarwal, Archana M , Swami, Umang , Rachoin, Jean-Sebastien , Guha, Avirup

Mayo Clinic

JNCI Cancer Spectrum | November 26, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/jncics/pkaf113 | PMID 41308174 Get It

Abstract Background Socioeconomic position (SEP) is a fundamental social determinant of health (SDoH) contributing to observed disparities in cancer and cardiovascular (CV) care among individuals with prostate cancer (PC). Understanding the influence of SEP on CV health is essential for addressing outcome inequities within this population. Methods We conducted a retrospective study utilizing Surveillance, Epidemiology, and End Results (SEER)-Medicare to evaluate CV outcomes in patients ≥65 years with PC from 2009 to 2017. We studied the impact of SEP on cardiovascular events (CVEs), cardiovascular mortality (CVm), PC-specific mortality (PCsm), and all-cause mortality. CVE, CVm, and PCsm were analyzed using competing risk models and all-cause mortality with Cox proportional hazards models. A subgroup analysis was performed in Non-Hispanic Black and Non-Hispanic White individuals. Results We included 141 242 patients of whom 76 844 were in high SEP areas (45.6%) and 64 398 in low SEP ones (54.4%). Both groups had a mean age of 72 years; patients in low SEP areas were 67.5% Non-Hispanic White, 34.4% having diabetes, 73.3% hypertension, and 67.7% dyslipidemia versus the high SEP group with 85.6% Non-Hispanic White, 30.4% diabetes, 69.9% hypertension, and 70.7% dyslipidemia. Patients in low SEP areas had higher risks of CVm (subdistribution hazard ratio [sHR] = 1.18, 95% CI = 1.12 to 1.25), PCsm (sHR = 1.12, 95% CI = 1.06 to 1.17), CVE (sHR = 1.07, 95% CI = 1.04 to 1.09), and all-cause mortality (HR 1.16, 95% CI = 1.13 to 1.20). Accentuated results were shown in the Non-Hispanic Black subgroup. Conclusion Adverse SEP plays a significant role in shaping outcomes among older patients with PC, contributing to elevated risks of adverse CV and survival outcomes.
Knowledge, Attitude and Practices of Physicians in Pakistan towards Onco-Hypertension: A Cross-sectional Study
Yaqub, Sobia, Saddique, Muhammad Nabeel, Shahid, Fatima , Hashmi, Mahrukh, Rehman, Umar , Alfadul, Esraa S. A. , Javed, Komal, Jabeen, Hafiza Safana, Khokhar, Muhammad Abbas, Iqbal, Inbsaat, Saddique, Muhammad Nabeel , Rehman, Ummi Aiman, Javed, Komal, Jha, Anurag, Akram, Amina , Iqbal, Inbsaat

Mayo Clinic

No container title available | November 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7868022/v1 Get It

Abstract Background Onco-hypertension, the interplay between cancer and hypertension, is an emerging specialty highlighting the bidirectional relationship between carcinogenesis, anticancer therapies, and blood pressure regulation. In Pakistan, data on physicians’ awareness and management of onco-hypertension are limited, yet critical given the rising global burden of cancer (24.5 million new cases; 9.6 million deaths in 2017) and hypertension (7.6 million annual deaths) worldwide. Methods A cross-sectional survey was conducted from May to October 2023 among physicians in oncology, internal medicine, cardiology, and allied specialties across tertiary hospitals, private clinics, and teaching institutions in Pakistan. A self-structured questionnaire, covering sociodemographic, knowledge, attitudes, and clinical practices, was distributed online and in person. Descriptive statistics summarized respondent characteristics, and inferential tests (t-tests, ANOVA) examined associations (p < 0.05). Results Mean respondent age was 37.5 ± 7.8 years; 58% male. Specialty distribution: internal medicine (45%), oncology (16%), cardiology (17%), nephrology (8%), pulmonology (13%), and others (1%). Nearly half (49%) rated their onco-hypertension knowledge as “average,” and 62% reported challenges managing hypertensive cancer patients. Key perceived causes in previously normotensive patients were anxiety (48%) and corticosteroid use (40%). Sixty-three percent sometimes adjusted antihypertensive regimens based on cancer therapies, and 80% endorsed the necessity of interdisciplinary coordination for optimal management. Conclusion Pakistani physicians demonstrate moderate understanding of onco-hypertension with prevalent management challenges. Findings underscore the need for targeted educational initiatives, validated clinical guidelines, and structured interdisciplinary collaboration to improve cardiovascular outcomes in cancer care.
Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis
Colombel, J.F., Ponich, Terry, Longman, Randy , Алексеева, О. П., Marta, Carmen-Ioana, Charles, Lorna, Rubin, DT, Afzali, Anita , Siegmund, Britta , Danese, Silvio , Jovanović, Igor , Bossuyt, Patrick M. , Petersen, Anne Sohrt , Loftus, Edward V. , Wolf, Douglas C.

Mayo Clinic

Zeitschrift für Gastroenterologie | November 25, 2025 | Volume: 60 | Issue: 08 | Pages: e428-e428

10.1055/s-0042-1754606 Get It

Verschluss perianaler Fisteln bei Patient:innen unter Ustekinumab: Ergebnisse der Studien SEAVUE und STARDUST
Kuehbacher, T, Peyrin-Biroulet, L, Gasink, Christopher , Hoops, Timothy, Izanec, James , Nazar, M, Bravatà, Ivana, Lahaye, Marjolein, Sands, BE, Kuehbacher, Tanja, Peyrin‐Biroulet, Laurent , Panaccione, Remo , Ma, T, Irving, Peter Miles , Loftus, Edward V. , Danese, Silvio

Mayo Clinic

Zeitschrift für Gastroenterologie | November 25, 2025 | Volume: 60 | Issue: 08 | Pages: e425-e426

10.1055/s-0042-1754603 Get It

Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
Cliff, Edward R. Scheffer , Simon, Florian , Hilal, Talal , Seymour, John F. , Lew, Thomas E, Simon, Florian , Hilal, Talal , Anderson, Mary Ann, Thompson, Philip A , Seymour, John F , Lew, Thomas Eliot , Anderson, Mary Ann

Mayo Clinic

Journal of Clinical Oncology | November 21, 2025 | Volume: 44 | Issue: 3 | Pages: 254-256

10.1200/jco-25-01695 | PMID 41270246 Get It

Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease
Vermeire, Séverine , Colombel, Jean–Frédéric, Panaccione, Remo , Beck, Kendall , Gisbert, Javier P. , Dubcenco, Elena, Klaff, Justin, Naling, Grace, Ford, Sharanya, Remple, Valencia P., Joshi, Namita , Suravaram, Smitha, Duncan, Benjamin , Wick-Urban, Bettina, Danese, Silvio , Panaccione, Remo , Chaparro, María , Gisbert, Javier P , Loftus, Edward V , Vermeire, Séverine , Danese, Silvio , Peyrin‐Biroulet, Laurent , Wang, Yibo , Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | November 19, 2025 | Volume: 20 | Issue: 1 | Pages: No page available

10.1093/ecco-jcc/jjaf198 | PMID 41264726 Get It

Abstract Background and Aims Upadacitinib (UPA)—an oral, reversible selective Janus kinase inhibitor—has a favorable benefit–risk profile for patients with Crohn’s disease (CD) and ulcerative colitis (UC). We evaluated the benefit–risk of UPA in select subgroups with CD or UC. Methods Patients were randomized to UPA 45 mg (UPA45) once daily (QD) or placebo (PBO) induction for 12 (CD: U-EXCEED, U-EXCEL) or 8 weeks (UC: U-ACHIEVE, U-ACCOMPLISH). Clinical responders were re-randomized to QD UPA 15 mg (UPA15), UPA 30 mg (UPA30), or PBO for 52-week maintenance (CD: U-ENDURE; UC: U-ACHIEVE). This exploratory post hoc analysis assessed efficacy and safety outcomes (adverse events of special interest [AESIs]: serious infections, major adverse cardiovascular [CV] events, malignancies, and venous thromboembolic events) by CV risk, prior treatment failure, and age. Results This analysis included 1021 patients with CD and 1097 with UC during induction, and 673 with CD and 746 with UC during maintenance. Improved efficacy outcomes comparable to the overall study populations were observed with UPA versus PBO across subgroups. Patients receiving UPA30 generally showed numerically higher rates of improvements versus UPA15. AESI rates were generally comparable between UPA and PBO across subgroups except for numerically higher rates of herpes zoster and serious infections in CD with UPA. Conclusions UPA resulted in consistent benefit versus placebo across CV risk, prior treatment failure, and age subgroups. No treatment differences were seen in AESIs across subgroups except herpes zoster and serious infections, reinforcing the favorable benefit–risk profile for UPA in CD and UC seen in the overall study populations. Clinical trial numbers NCT02819635, NCT03653026, NCT03345836, NCT03345849, NCT03345823
Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis
Desai, Aakash , Habib, Hany , Khataniar, Himsikhar , Sehgal, Priya , Kochhar, Gursimran , Sehgal, Priya , Kochhar, Gursimran S , Desai, Aakash , Farraye, Francis A. , Barnes, Edward L. , Hashash, Jana G.

Mayo Clinic

Inflammatory Bowel Diseases | November 19, 2025 | Volume: 32 | Issue: 5 | Pages: 869-874

10.1093/ibd/izaf301 | PMID 41365321 Get It

Abstract Introduction There are limited data on the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) on the risk of recurrent pouchitis after ileal pouch–anal anastomosis (IPAA) for ulcerative colitis (UC). Methods A retrospective cohort study was conducted in the TriNetX Research Network in adult patients with obesity and IPAA for UC with a history of pouchitis in whom a GLP-1RA was initiated compared to those patients in whom a GLP-1RA was not initiated. The primary outcome was the risk of recurrent pouchitis within 12 months. The secondary outcomes were mean number of antibiotic prescriptions, anti-diarrheal medication use, Crohns-like disease of pouch (CLDP), and pouch excision. One-to-one propensity score matching was performed. Results We identified 43 UC-IPAA patients with obesity and history of pouchitis (mean age 51.7 ± 14.7 years, mean body mass index [BMI] 34.4 ± 6 kg/m2, 60.4% female). After propensity score matching, the GLP-1RA cohort had a significantly decreased risk of recurrent pouchitis (26.3% vs 52.6%; adjusted odds ratio [aOR], 0.32; 95% CI, 0.12-0.84) compared to the control cohort. Mean antibiotic prescriptions were numerically lower in the GLP-1RA cohort (2 vs 4.4, P = .16). Anti-diarrheal medication use was lower in the GLP-1RA cohort (18.4% vs 47.3%; aOR, 0.23; 95% CI, 0.07-0.67). There was no difference in the risk of CLDP. Zero patients required pouch excision in both cohorts. Conclusion Our study in a small cohort of patients with UC-IPAA and obesity with a history of pouchitis showed that GLP-1RA use was associated with decreased risk of recurrent pouchitis and anti-diarrheal medication use.
Outcomes of Transvenous Lead Removal in Patients With Prior Mediastinal Radiation
Patel, Harsh , Munir, Muhammad Bilal , Sugrue, Alan , Tan, Nicholas Y. , Munoz, Freddy Del‐Carpio , Cha, Yong‐Mei , Mulpuru, Siva K. , Deshmukh, Abhishek , Agarwal, Siddharth , DeSimone, Daniel, Munir, Muhammad Bilal , Agarwal, Siddharth , Agarwal, Siddharth, Asad, Zain Ul Abideen , DeSimone, Daniel C. , DeSimone, Christopher V. , Deshmukh, Abhishek

Mayo Clinic

Journal of Cardiovascular Electrophysiology | November 18, 2025 | Volume: 37 | Issue: 1 | Pages: 186-189

10.1111/jce.70192 | PMID 41250637 Get It

ABSTRACT Background Transvenous lead removal (TLR) in patients with a history of mediastinal radiation poses unique challenges due to potential radiation‐induced fibrosis, vascular changes, and anatomical distortion, which may increase procedural complexity and complication risk. However, contemporary data on clinical outcomes in this population remain limited. Methods We analyzed the National Readmissions Database (2016–2021) to identify adults (≥ 18 years) undergoing TLR. Patients were stratified by prior mediastinal radiation. Baseline characteristics were compared using standard statistical tests. Multivariable logistic regression was used to evaluate the association between prior mediastinal radiation and in‐hospital outcomes, 30‐day mortality, and 30‐day readmissions after adjustment for demographics and comorbidities. Results A total of 48,985 patients underwent TLR, of whom 735 (1.5%) had a history of mediastinal radiation. Compared with patients without radiation, those with prior radiation were older (70.1 vs. 66.2 years, p < 0.01), were more frequently females (38.2% vs. 31.6%, p < 0.01), and had higher rates of valvular heart disease, atrial fibrillation, and peripheral vascular disease. Adjusted analyses demonstrated no increased risk of in‐hospital mortality (2.3% vs. 3.4%; adjusted odds ratio [aOR] 0.65, 95% confidence interval [CI] 0.41–1.18, p = 0.29) or major complications, including cardiac arrest, pericardial complications, vascular injury, pulmonary complications, or embolic events. Similarly, (3.6% vs. 5.3%; aOR 0.76, 95% CI 0.48–1.43, p = 0.35) and 30‐day all‐cause readmissions (8.7% vs. 9.1%; aOR 0.81, 95% CI 0.64–1.28, p = 0.70) were not significantly different between groups. Subgroup analyses by indication for TLR (infection vs. mechanical complication) revealed no differences in outcomes. Conclusion Despite theoretical concerns, prior mediastinal radiation was not associated with excess procedural risk or worse short‐term outcomes after TLR. These findings may inform procedural planning and risk counseling in clinical practice.